OTCMKTS:GTHP Guided Therapeutics (GTHP) Stock Price, News & Analysis $0.11 +0.01 (+8.80%) As of 04/25/2025 09:30 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsSEC FilingsShort InterestBuy This Stock About Guided Therapeutics Stock (OTCMKTS:GTHP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Guided Therapeutics alerts:Sign Up Key Stats Today's Range$0.11▼$0.1150-Day Range$0.08▼$0.1352-Week Range$0.06▼$0.23Volume399 shsAverage Volume16,331 shsMarket Capitalization$8.59 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewGuided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.Read More… Receive GTHP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Guided Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GTHP Stock News HeadlinesGuided Therapeutics Announces Filing of Application for NMPA Approval to Market and Sell LuViva in ChinaOctober 22, 2024 | finance.yahoo.comGuided therapeutics director buys shares worth $150,000October 4, 2024 | investing.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 28, 2025 | Porter & Company (Ad)Guided Therapeutics Inc (GTHP)August 21, 2024 | investing.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Q1 2024 Earnings Call TranscriptMay 2, 2024 | msn.comLeading Cervical Cancer Doctors Support Approval of LuViva in China Based on Preliminary Review of Clinical Trial ResultsFebruary 20, 2024 | finance.yahoo.comLeading Cervical Cancer Doctors Support Approval of LuViva in China Based on Preliminary Review of Clinical Trial ResultsFebruary 20, 2024 | businesswire.comGuided Therapeutics IncNovember 20, 2023 | thestreet.comSee More Headlines GTHP Stock Analysis - Frequently Asked Questions How have GTHP shares performed this year? Guided Therapeutics' stock was trading at $0.15 at the beginning of 2025. Since then, GTHP stock has decreased by 27.5% and is now trading at $0.1088. View the best growth stocks for 2025 here. How were Guided Therapeutics' earnings last quarter? Guided Therapeutics, Inc. (OTCMKTS:GTHP) released its earnings results on Monday, March, 31st. The company reported ($0.02) earnings per share for the quarter. How do I buy shares of Guided Therapeutics? Shares of GTHP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Guided Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Guided Therapeutics investors own include Cornerstone Strategic Value Fund (CLM), Intel (INTC), Beam Therapeutics (BEAM), ChargePoint (CHPT), CSX (CSX), Warner Bros. Discovery (DISCA) and Enbridge (ENB). Company Calendar Last Earnings3/31/2025Today4/28/2025Next Earnings (Estimated)5/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Electromedical equipment Sub-IndustryMedical Equipment Current SymbolOTCMKTS:GTHP CIK924515 Webwww.guidedinc.com Phone(770) 242-8723Fax770-242-8639Employees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,490,000.00 Net MarginsN/A Pretax Margin-5,660.53% Return on EquityN/A Return on Assets-151.93% Debt Debt-to-Equity RatioN/A Current Ratio0.17 Quick Ratio0.07 Sales & Book Value Annual Sales$100,000.00 Price / Sales85.85 Cash FlowN/A Price / Cash FlowN/A Book Value($0.13) per share Price / Book-0.84Miscellaneous Outstanding Shares78,910,000Free Float21,673,000Market Cap$8.59 million OptionableNot Optionable Beta0.42 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (OTCMKTS:GTHP) was last updated on 4/28/2025 by MarketBeat.com Staff From Our PartnersTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored‘Wheels Are Falling Off’ the U.S. Stock MarketThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Guided Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Guided Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.